Related Experiment Videos
Effect of FPL57787 in exercise-induced asthma
Clinical Allergy
|January 1, 1980
Summary
A new oral chromone, FPL57787, significantly protected patients against exercise-induced asthma (EIA) by reducing lung function decline post-exercise. This study highlights FPL57787
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Trials
Background:
- Extrinsic asthma is a common condition often triggered by environmental factors.
- Exercise-induced asthma (EIA) significantly impacts patients' quality of life.
- New therapeutic agents are needed to effectively manage EIA.
Purpose of the Study:
- To evaluate the efficacy of a novel oral chromone, FPL57787, in preventing exercise-induced asthma (EIA).
- To assess the protective effects of FPL57787 against exercise-induced bronchoconstriction.
Main Methods:
- A randomized, double-blind, placebo-controlled study was conducted.
- Ten patients with extrinsic asthma participated in the trial.
- Exercise testing involved treadmill running, with lung function (FEV1, FVC, MMEF) monitored before and after exercise.
Main Results:
- FPL57787 demonstrated significant protection against the maximum percentage fall in FEV1, FVC, and MMEF post-exercise compared to placebo (P < 0.01).
- A small but significant increase in FEV1 was observed 2 hours after FPL57787 administration.
- No significant changes in FVC or MMEF were noted at the 2-hour mark.
Conclusions:
- FPL57787 is effective in preventing exercise-induced asthma.
- The oral chromone FPL57787 offers significant protection against exercise-induced lung function decline.
- Further research into FPL57787 as a treatment for EIA is warranted.